[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356657-105":59,"doc-detail-356657-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cd28-co-stimulatory-domain-enhances-efficacy-of-cert-cell-therapy-compared-to-4-1bb-in-an-ovarian-cancer-mouse-model","CD28 co-stimulatory domain enhances efficacy of CERT cell therapy compared to 4-1BB in an ovarian cancer mouse model","","CD28 co-stimulatory domain enhances efficacy of chimeric endocrine receptor (CER) T cells targeting follicle stimulating hormone receptor (FSHR) in an ovarian cancer mouse model. The study compares CD28ζ and 4-1BBζ intracellular domains in FSH-CERT cells engineered in ID8-FSHR mice. FSH-CD28ζ CERT cells show greater cytotoxicity, proliferation, and cytokine secretion in vitro and in vivo. In vivo, CD28ζ reduces tumor burden and extends survival versus 4-1BBζ and control cells, though efficacy is limited by T cell exhaustion marked after 7 days.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cd28-co-stimulatory-domain-enhances-efficacy-of-cert-cell-therapy-compared-to-4-1bb-in-an-ovarian-cancer-mouse-model/356657/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cd28-co-stimulatory-domain-enhances-efficacy-of-cert-cell-therapy-compared-to-4-1bb-in-an-ovarian-cancer-mouse-model/356657.png","ImageObject",300,407,{"name":92,"@type":93},"Riley West","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What CER T cell strategy is evaluated in this study?","Question",{"text":112,"@type":113},"The study evaluates FSH-CER T cells engineered to target FSH receptor (FSHR) in a syngeneic ovarian cancer mouse model (ID8-FSHR). It compares two co-stimulatory/intracellular domains: CD28ζ versus 4-1BBζ.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do CD28ζ and 4-1BBζ CER T cells compare in vitro?",{"text":117,"@type":113},"FSH-CD28ζ CERT cells exhibit enhanced cytotoxicity, proliferation, and cytokine secretion compared with FSH-4-1BBζ CER T cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the main in vivo outcome and what limits efficacy?",{"text":121,"@type":113},"In the ID8-FSHR model, FSH-CD28ζ CERT cells significantly reduce tumor burden and extend survival. However, therapeutic efficacy is compromised by T cell exhaustion, with high exhaustion marker expression after 7 days.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356657,1790148624,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCD28 co-stimulatory domain enhances efficacy of CERT cell therapy compared to 4-1BB in an ovarian cancer mouse model  \nNolan J. Beatty1,2,3, Min Ma3, Payal Goala1,2,3, Shannon McSain3, Sae Bom Lee4, Justin C. Boucher1, Meredith L. Stone3, Yun Pyo Kang4, Eduardo Cortes-Gomez5, Jianmin Wang3, Jun Qu3 & Marco L. Davila3􀀍  \nOvarian cancer remains a significant cause of cancer-related mortality, with epithelial ovarian cancer (EOC) being the most common subtype. Despite advances in treatment, the 5-year survival rate for late-stage EOC remains low due to factors such as tumor heterogeneity and an immunosuppressive tumor microenvironment (TME). This study investigates the therapeutic potential of chimeric endocrine receptor (CER) T cells engineered to express follicle stimulating hormone (FSH) in a syngeneic mouse model of EOC expressing follicle stimulating hormone receptor (ID8-FSHR). We compared two different co-stimulatory domains—CD28ζ and 4-1BBζ—in FSH-CERT cells and found that FSH-CD28ζ CERT cells exhibited enhanced cytotoxicity, proliferation, and cytokine secretion in vitro and in vivo. In the ID8-FSHR mouse model, FSH-28ζ CERT cells significantly reduced  \ntumor burden and extended survival compared to FSH-hBBζ and control CERT cells. However, the therapeutic efficacy was compromised by T cell exhaustion, with all FSH-CERT cells expressing high levels of exhaustion markers after 7 days. In summary, incorporating a CD28ζ costimulatory domain enhances the efficacy of FSH-CERT cells, highlighting their therapeutic potential in ovarian cancer and supporting the development of strategies to mitigate immune exhaustion.  \nOvarian cancer is responsible for 2.3% of all female cancer deaths in the United States with over 12,000 women dying each year from the disease1,2. Due to the lack of symptoms, ovarian cancer is usually diagnosed at a late stage when the cancer has spread throughout the abdominal cavity3–5. The 5-year survival rate is approximately 30% for patients diagnosed with late-stage disease6–8.  \nThe majority of ovarian cancers are EOC3,9. Attempts to target solid tumors with CAR T cells have yielded mixed results, largely due to inadequate T cell trafficking, immunosuppressive signaling, tumor heterogeneity, and a hostile TME. TME factors including hypoxia, acidity, dense stroma, cancer-associated fibroblasts (CAFs), inflammatory cytokines, and suppressive immune cells such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) limit CAR T cell efficacy10–17. EOC generally metastasizes to the peritoneal tissue and the omentum causing blockage of the lymphatic system which leads to ascites18. The aggressive tumor growth, immunosuppressive TME, and metastasis observed in human disease are recapitulated in the ID8 syngeneic mouse model transduced with vascular endothelial growth factor alpha (Vegf-a) and beta-defensin 129 (Defb29) which increases tumor burden, vascular growth and ascites and shortens survival19. We used C57BL/6J mice challenged with ID8 cells for in vivo studies to test FSH-CER T cells, providing a platform for investigating the disease’s pathogenesis and therapeutic interventions.  \nRecently, FSHR was found to be expressed in nearly all ovarian cancer subtypes and targeting FSHR⁺ tumors with newly developed CER T cells significantly reduced tumor burden and prolonged survival in both patientderived xenograft (PDX) and solid tumor models20. Unlike traditional chimeric antigen receptors (CARs), which rely on synthetic single-chain variable fragments (scFvs) derived from monoclonal antibodies to recognize tumor antigens, CERs utilize naturally occurring peptide hormones, such as follicle stimulating hormone (FSH), as their extracellular binding domain. This approach capitalizes on native ligand-receptor specificity, potentially improving selectivity and reducing the risk o","cbCaiqjEHFf2Vpy3","https://ap.wps.com/l/cbCaiqjEHFf2Vpy3","pdf",5121325,17,"English","# Abstract\n## Background and rationale\n## CER T cell design and comparison\n## Findings and implications\n## Results overview","[{\"question\":\"What CER T cell strategy is evaluated in this study?\",\"answer\":\"The study evaluates FSH-CER T cells engineered to target FSH receptor (FSHR) in a syngeneic ovarian cancer mouse model (ID8-FSHR). It compares two co-stimulatory/intracellular domains: CD28ζ versus 4-1BBζ.\"},{\"question\":\"How do CD28ζ and 4-1BBζ CER T cells compare in vitro?\",\"answer\":\"FSH-CD28ζ CERT cells exhibit enhanced cytotoxicity, proliferation, and cytokine secretion compared with FSH-4-1BBζ CER T cells.\"},{\"question\":\"What is the main in vivo outcome and what limits efficacy?\",\"answer\":\"In the ID8-FSHR model, FSH-CD28ζ CERT cells significantly reduce tumor burden and extend survival. However, therapeutic efficacy is compromised by T cell exhaustion, with high exhaustion marker expression after 7 days.\"}]","CD28 co-stimulatory domain enhances efficacy of CERT cell therapy compared to 4-1BB in an ovarian cancer mouse model | PDF",1790126610,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4131b9782a98f14248eff05b5814315.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67426df3494733fd51e172ca5447e9dc.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b87c5a5c7e9e7b56a46b14a7fce4bc4.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fa38a05ec6190d70a9ddfd05307abc6.webp",980,1287]